https://uvahealth.com/findadoctor/Craig-Portell-1427218205
Newly Approved Triplet Regimen Boosts Survival in R/R LBCL: Craig Portell, MD
ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from February as an alternative to more complex and time-consuming regimens in the setting of relapsed/refractory large B-cell lymphoma (R/R LBCL).